FDA
-
-
-
-
-
-
-
Eloxx Pharmaceuticals (ELOX) Provides Program Updates on ELX-02 and ZKN-013
-
-
-
-
-
-
-
Eloxx Pharmaceuticals Reports First Quarter 2023 Financial and Operating Results and Provides Business Update
-
-
-
-
-
-
-
Eloxx Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application for ZKN-013
-
-
-
-
-
-
-
Eloxx Pharmaceuticals Announces Reverse Stock Split Effective
-
-
-
-
-
-
-
Eloxx Pharmaceuticals (ELOX) Reports Topline Results from Phase 2 Combination Clinical Trial of ELX-02
-
-
-
-
-
-
-
Eloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Provides Business Update
-
-
-
-
-
-
-
Eloxx Pharmaceuticals Reports Positive Topline Results from Monotherapy Arms of Phase 2 Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients
-
322,245 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

